To assess miRisten effects on primary human MDS cell in vivo repopulating capacity, we treated MDS CD34+ cells ex vivo for 72 h with SCR control, miRisten, DAC, or the miRisten/DAC combination and transplanted treated cells into NSGS mice (Figure 4G). The gene discussed is CD34; the disease is myelodysplastic syndrome.